Skandinaviska Enskilda Banken AB publ Purchases 5,189 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Skandinaviska Enskilda Banken AB publ grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 30.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,290 shares of the company’s stock after buying an additional 5,189 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Vera Therapeutics were worth $938,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC purchased a new position in Vera Therapeutics in the fourth quarter worth $34,000. E Fund Management Co. Ltd. grew its stake in Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after buying an additional 1,130 shares during the last quarter. KBC Group NV increased its position in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares in the last quarter. Arizona State Retirement System raised its stake in Vera Therapeutics by 22.9% in the fourth quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock valued at $532,000 after buying an additional 2,348 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Vera Therapeutics by 27.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $568,000 after acquiring an additional 2,882 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $28.07 on Tuesday. Vera Therapeutics, Inc. has a 52-week low of $25.99 and a 52-week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.79 billion, a PE ratio of -10.75 and a beta of 1.17. The business has a 50-day simple moving average of $32.73 and a 200-day simple moving average of $39.58.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. On average, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 21.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

VERA has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective for the company. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price on the stock. Wells Fargo & Company began coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target for the company. Finally, Guggenheim increased their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Vera Therapeutics presently has an average rating of “Buy” and an average target price of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.